<- Go Home
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Market Cap
$12.0B
Volume
387.1K
Cash and Equivalents
$295.7M
EBITDA
-$306.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$705.5M
Profit Margin
95.25%
52 Week High
$544.25
52 Week Low
$265.00
Dividend
N/A
Price / Book Value
19.20
Price / Earnings
-40.60
Price / Tangible Book Value
19.43
Enterprise Value
$11.3B
Enterprise Value / EBITDA
-36.87
Operating Income
-$307.5M
Return on Equity
41.22%
Return on Assets
-15.78
Cash and Short Term Investments
$1.1B
Debt
$346.4M
Equity
$625.7M
Revenue
$740.6M
Unlevered FCF
-$61.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium